PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer
Li-Li Long(Southern Medical University), Zhong‐Yi Dong(Nanfang Hospital)
Cited by 33
Related Papers
Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
|Journal for ImmunoTherapy of Cancer|2020|63
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy
|Nature Communications|2023|58
PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy
|Cancer Cell|2025|30
Increased expression of OCT4 is associated with low differentiation and tumor recurrence in human hepatocellular carcinoma
|Pathology - Research and Practice|2012|29